The acute phase response and atherosclerosis

Drug Discovery Today: Disease Mechanisms

Volumn 1, Issue 1, 2004, Pages 17-22

  Lowenstein, Charles ^a   Matsushita, Kenji ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTISENSE OLIGONUCLEOTIDE; C REACTIVE PROTEIN; CCAAT ENHANCER BINDING PROTEIN; CHEMOKINE; CHOLESTEROL; GLYCOPROTEIN GP 130; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; RECEPTOR ANTIBODY; RECOMBINANT PROTEIN; RIBOZYME; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; ENDOTHELIUM LESION; HUMAN; HYPERTENSION; IMMUNE RESPONSE; MACROPHAGE ACTIVATION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 23744497661     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2004.08.001     Document Type: Review

References (39)

1. 2001. Heart and Stroke Statistical Update, American Heart Association.
2. Ridker, P.M. et al. (1998) Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351, 88-92
3. Ridker, P.M. et al. (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101, 1767-1772
4. Ridker, P.M. et al. (2001) Soluble P-selectin and the risk of future cardiovascular events. Circulation 103, 491-495
5. Hwang, S.J. et al. (1997) Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96, 4219-4225
6. Ridker, P.M. et al. (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843
7. Kuller, L.H. et al. (1996) Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am. J. Epidemiol. 144, 537-547
8. Koenig, W. et al. (1999) C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99, 237-242
9. Ridker, P.M. et al. (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973-979
10. Tracy, R.P. et al. (1997) Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb. Vasc. Biol. 17, 1121-1127
11. Ridker, P.M. et al. (1998) Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97, 425-428
12. Harris, T.B. et al. (1999) Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med. 106, 506-512
13. Danesh, J. et al. (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br. Med. J. 321, 199-204
14. Lowe, G.D. et al. (2001) C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb. Vasc. Biol. 21, 603-610
15. Ridker, P.M. et al. (2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. J. Am. Med. Assoc. 285, 2481-2485
16. Albert, M.A. et al. (2001) Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. J. Am. Med. Assoc. 286, 64-70
17. Gabay, C. and Kushner, I. (1999) Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340, 448-454
18. Uhlar, C.M. and Whitehead, A.S. (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 265, 501-523
19. Rader, D.J. (2000) Inflammatory markers of coronary risk. N. Engl. J. Med. 343, 1179-1182
20. Janeway, C.A. Jr and Medzhitov, R. (2002) Innate immune recognition. Annu. Rev. Immunol. 20, 197-216
21. Liu, Y.J. (2001) Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106, 259-262
22. Guermonprez, P. et al. (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20, 621-667
23. Banchereau, J. and Steinman, R.M. (1998) Dendritic cells and the control of immunity. Nature 392, 245-252
24. Levy, D.E. and Lee, C.K. (2002) What does Stat3 do? J. Clin. Invest. 109, 1143-1148
25. Yoo, J.Y. et al. (2002) Specific ablation of Stat3beta distorts the pattern of Stat3-responsive gene expression and impairs recovery from endotoxic shock. Cell 108, 331-344
26. Morley, J.J. and Kushner, I. (1982) Serum C-reactive protein levels in disease. Ann. N.Y. Acad. Sci. 389, 406-418
27. Desiderio, S. and Yoo, J.Y. (2003) A genome-wide analysis of the acute-phase response and its regulation by Stat3beta. Ann. N.Y. Acad. Sci. 987, 280-284
28. Yoo, J.Y. and Desiderio, S. (2003) Innate and acquired immunity intersect in a global view of the acute-phase response. Proc. Natl. Acad. Sci. USA 100, 1157-1162
29. Wang, L. et al. (2003) Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 302, 1578-1581
30. Gimbrone, M.A. Jr et al. (2000) Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann. N.Y. Acad. Sci. 902, 230-239 (239-240; discussion)
31. Mann, M.J. et al. (1999) Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc. Natl. Acad. Sci. USA 96, 6411-6416
32. Mahieu, M. et al. (1994) Construction of a ribozyme directed against human interleukin-6 mRNA: evaluation of its catalytic activity in vitro and in vivo. Blood 84, 3758-3765
33. Jones, S.A. et al. (2001) The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 15, 43-58
34. Nowell, M.A. et al. (2003) IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J. Immunol. 171, 320
35. Nakahara, H. et al. (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 48, 1521-1529
36. Grandis, J.R. et al. (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. USA 97, 4227-4233
37. Mach, F. et al. (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature (London) 394, 200-203
38. Namiki, M. et al. (2004) Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis 172, 21-29
39. Veillard, N.R. et al. (2004) Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ. Res. 94, 253-261